 Connection
Andrey Soares to Retrospective Studies
This is a "connection" page, showing publications Andrey Soares has written about Retrospective Studies.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.113 |
|
|
|
-
Maruzzo M, Poprach A, Buti S, Bamias A, Zakopoulou R, DE Giorgi U, Kucharz J, Formisano L, Buttner T, Zucali PA, Li H, Incorvaia L, Kopp RM, Messina C, Kopecky J, Fornarini G, Landmesser J, Rebuzzi SE, Nasso C, Fay AP, Bhuva D, Pinto A, Buchler T, Pichler R, Kanesvaran R, Soares A, Massari F, Monteiro FS, Dos Santos Filho IA, Porta C, Basso U, Santoni M. Real-world comparison of the effectiveness and safety of immune-based combinations in elderly patients with advanced renal cell carcinoma (ARON-1 study). Minerva Urol Nephrol. 2026 Apr; 78(2):210-221.
Score: 0.017
-
Mollica V, Massari F, Fujita K, Giannatempo P, Grande E, Büttner T, Bourlon MT, Taha T, Fukuokaya W, Myint ZW, Pichler R, Binz K, Molina-Cerrillo J, Kopecky J, de Liaño AG, Kucharz J, Fiala O, Matrana MR, Kopp RM, Di Civita MA, Zgura A, Ansari J, Kihnel R, De Felice F, Angel M, Monteiro FSM, Soares A, Urun Y, Buti S, Santini D, Santoni M. Real-world effectiveness of avelumab, pembrolizumab, and enfortumab vedotin in patients with advanced urothelial carcinoma with squamous differentiation (ARON-2EV). Cancer Immunol Immunother. 2026 Mar 24; 75(4).
Score: 0.016
-
Cerbone L, Roviello G, Calabrò F, Taha T, Grande E, Binz K, Kanesvaran R, Pirstuk A, Fiala O, Molina-Cerrillo J, Alonso-Gordoa T, Rizzo A, Pichler R, Myint ZW, Poprach A, Facchini G, Bohuslav M, Studentova H, Morelli F, Buchler T, Mennitto A, Tural D, Formisano L, Orejana I, Catalano M, Buti S, Monteiro FSM, Soares A, Gupta S, Massari F, Santoni M. Liver metastases in advanced urothelial carcinoma (ARON-2): do pembrolizumab and avelumab make a difference in a poor-prognosis scenario? Front Immunol. 2026; 17:1667155.
Score: 0.016
-
Kopp RM, Massari F, Grande E, Schieber TJ, Ürün Y, Kopecký J, Molina-Cerrillo J, Basso U, Kucharz J, Büttner T, Pichler R, Fiala O, Myint ZW, Galli L, Buchler T, Rizzo M, Bolek H, Bourlon MT, Conteduca V, Pinto A, Rizzo A, Rosellini M, Roviello G, Zgura A, Mollica V, Partl A, Yildirim A, Akova U, Buti S, Monteiro FSM, Soares A, Porta C, Bilen MA, Li H, Santoni M. Real-world evidences on adjuvant Pembrolizumab for renal cell carcinoma: results from the multicenter real-world ARON-1 study. Cancer Immunol Immunother. 2025 Nov 14; 74(12):374.
Score: 0.016
-
Molina-Cerrillo J, Roviello G, Bourlon MT, Studentova H, Fiala O, Cerbone L, Kucharz J, Ansari J, Zeppellini A, Taha T, Buti S, Ürün Y, Scagliarini S, Li H, Sunela K, Park SH, Rizzo M, Zgura A, Chiari R, Seront E, Catalano M, Ghosn M, Filosa A, Soares A, Massari F, Monteiro FSM, Grande E, Porta C, Bracarda S, Santoni M. Toxicity-related immunotherapy discontinuation and outcome in patients with advanced renal cell carcinoma treated with immune-based combinations (ARON-1 study). Int J Cancer. 2026 Mar 01; 158(5):1396-1405.
Score: 0.016
-
Massari F, Rosellini M, Melichar B, Grande E, Bourlon MT, Li H, Fiala O, Park SH, Fita MJJ, Taha T, Molina-Cerrillo J, Santini D, de Liañ AG, Büttner T, Scagliarini S, Manneh Kopp R, Zeppellini A, Ghosn M, Conteduca V, Bölek H, Rizzo A, Ansari J, Mollica V, Zgura A, Filosa A, Yildirim A, Akova U, Monteiro FSM, Buti S, Soares A, Bilen MA, Ürün Y, Santoni M. Sarcomatoid Differentiation in Renal Cell Carcinoma: Clinical and Pathologic Heterogeneity and Outcomes With Immune Checkpoint Inhibitors-Data From the ARON-1 Study. JCO Glob Oncol. 2025 Oct; 11:e2500376.
Score: 0.016
-
Mandel P, Groener D, Follacchio G, Ürün Y, Bourlon MT, Sabet A, Grünwald F, Tural D, Büttner T, Kopp RM, Taha T, Chun FK, Facchini G, Myint ZW, Seront E, Conteduca V, Quiroga MNG, Aurilio G, Palacios GA, Bögemann M, Roviello G, Matrana MR, Sammarco E, Laguado MIZ, Galli L, Ansari J, Danielli L, Molina-Cerrillo J, Rescigno P, Yazgan SC, Bastos DA, Jazieh AR, Monteiro FSM, Soares A, Massari F, Wenzel M, Capoccetti F, Santoni M. 177Lu-PSMA vs. cabazitaxel in patients with castration-resistant prostate cancer: Real-world efficacy and safety data from the ARON-3 study. Eur J Cancer. 2025 Oct 16; 229:115789.
Score: 0.016
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|